» Articles » PMID: 12756220

Effects of Pressure Overload on Extracellular Matrix Expression in the Heart of the Atrial Natriuretic Peptide-null Mouse

Overview
Journal Hypertension
Date 2003 May 21
PMID 12756220
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

This study tested the hypothesis that atrial natriuretic peptide has direct antihypertrophic actions on the heart by modulating expression of genes involved in cardiac hypertrophy and extracellular matrix production. Hearts of male, atrial natriuretic peptide-null and control wild-type mice that had been subjected to pressure overload after transverse aortic constriction and control unoperated hearts were weighed and subjected to microarray, Northern blot, and immunohistochemical analyses. Microarray and Northern blot analyses were used to identify genes that are regulated differentially in response to stress in the presence and absence of atrial natriuretic peptide. Immunohistochemical analysis was used to identify and localize expression of the protein products of these genes. Atrial natriuretic peptide-null mice demonstrated cardiac hypertrophy at baseline and an exaggerated hypertrophic response to transverse aortic constriction associated with increased expression of the extracellular matrix molecules periostin, osteopontin, collagen I and III, and thrombospondin, as well as the extracellular matrix regulatory proteins, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3, and the novel growth factor pleiotrophin compared with wild-type controls. These results support the hypothesis that atrial natriuretic peptide protects against pressure overload-induced cardiac hypertrophy and remodeling by negative modulation of genes involved in extracellular matrix deposition.

Citing Articles

The Impact of Natriuretic Peptides on Heart Development, Homeostasis, and Disease.

Giovou A, Gladka M, Christoffels V Cells. 2024; 13(11.

PMID: 38891063 PMC: 11172276. DOI: 10.3390/cells13110931.


Periostin is overexpressed, correlated with fibrosis and differs among grades of cardiomyocyte hypertrophy in myectomy tissue of patients with hypertrophic cardiomyopathy.

Ioakeimidis N, Pitsis A, Zegkos T, Ntelios D, Kelpis T, Papamitsou T PLoS One. 2023; 18(11):e0293427.

PMID: 37939043 PMC: 10631645. DOI: 10.1371/journal.pone.0293427.


The Multiple Roles of Periostin in Non-Neoplastic Disease.

Yang L, Guo T, Chen Y, Bian K Cells. 2023; 12(1).

PMID: 36611844 PMC: 9818388. DOI: 10.3390/cells12010050.


Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.

Omran F, Kyrou I, Osman F, Lim V, Randeva H, Chatha K Int J Mol Sci. 2022; 23(10).

PMID: 35628490 PMC: 9143441. DOI: 10.3390/ijms23105680.


Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.

Khomtchouk B, Lee Y, Khan M, Sun P, Mero D, Davidson M Expert Opin Drug Discov. 2022; 17(5):443-460.

PMID: 35258387 PMC: 9050939. DOI: 10.1080/17460441.2022.2047645.